Elahere's UK Launch: A New Era for Drug Pricing?
Update: 2025-09-29
Description
AbbVie launches its ovarian cancer guided missile drug, Elahere, in the UK at US prices, reigniting the global drug pricing debate. Will this bold move, following pressure from the Trump administration, set a new precedent for international medication costs and access to life-saving treatments? The outcome of AbbVie's negotiations with UK regulators could reshape the future of cancer drug funding worldwide.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
